Cần mọi người hướng dẫn tư vấn giúp đỡ về Nct03700905

Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy (IMSTAR-HN) The safety and scientific validity of

Đọc thêm

The IMSTAR-HN study compares neoadjuvant N and N ± I 6 months after adjuvant therapy versus standard therapy as first-line treatment for LA-HNSCC. Eligible patients have treatment-naive LA-HNSCC, East

Đọc thêm

Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy - No Study Results Posted.

Đọc thêm

Study NCT03700905 Submitted Date: October 8, 2018 (v1) Study Identification. Unique Protocol ID: CA209-934 : Brief Title: Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs

Đọc thêm

Surgically treated locally advanced head and neck squamous cell carcinoma often requires postoperative chemoradiation with high risk of acute and late toxicity. DFS after 2 years is approximately 70%.

Tên miền: www.mycancergenome.org Đọc thêm

NCT03700905, CA209-934: Conditions. Head and Neck Cancer. Treatments. Surgical resection of primary tumor, Adjuvant radio(-chemo)therapy, Neoadjuvant Nivolumab, Adjuvant Nivolumab, Adjuvant Nivolumab

Tên miền: www.smartpatients.com Đọc thêm

NCT03700905: EU: 1+3: Post-operative radio(-chemo) therapy 56-66 Gy + chemotherapy cisplatin 100 mg/m 2 on days 1, 22, 43: Nivolumab neoadjuvant within 2 weeks before surgery 3 mg/kg IV on day 1, ever

Đọc thêm

Inclusion Criteria: Informed of the investigational nature of this study and give written informed consent; Histologically or cytologically confirmed nasopharyngeal carcinoma, tumor staged as IVB (acc

Đọc thêm

Clinical trial for head and neck cancer , Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy

Tên miền: www.centerwatch.com Đọc thêm

Jul 1, 2022Introduction. Squamous cell carcinoma of the head and neck (HNSCC) is one of the most common malignancies in the world, accounting for over 90% of head and neck tumors in Asia and Europe []

Tên miền: www.sciencedirect.com Đọc thêm

NCT03700905: Phase 3: Interventional: No Results: Posted: 2018-10-09: Start: 2018-08-21: Results: None: Primary: None: Complete: None: Brief Summary: Multicenter randomized controlled phase III study

Tên miền: drugsheet.com Đọc thêm

Sep 9, 2020Another phase 3 clinical study, IMSTAR-HN (NCT03700905) is evaluating the potential of nivolumab, alone or in combination with ipilimumab, as immunotherapy vs standard follow up in surgical

Tên miền: www.researchgate.net Đọc thêm